Last year, Stada weighed a buyout to fend off an activist shareholder. Now, nearly six months after a proxy battle victory, it may find itself in a bidding war.

Surprise, surprise: Cancer drugmaker Tesaro is attracting takeover interest from a slew of companies eyeing its potential blockbuster niraparib.

If you’re looking for new drama at Sanofi this year, you might just be disappointed. The French drugmaker said Wednesday it’s expecting no big financial swings…

CEO John Milligan was asked to ponder his $30 billion in 2016 revenue—and answer this key question: Can you "grow company without an acquisition?”

Pfizer’s execs have said they’re not going to pause on dealmaking to wait for U.S. tax reform to free up cash. They may have another plan to drum up M&A…

BMS cut its 2017 guidance, but its I-O franchise remains strong—and one analyst suggests setbacks plus value could tag the company as a takeover target.

It took months, but growth-starved Johnson & Johnson and longtime solo flyer Actelion finally have a deal that’ll make both parties happy.

Could Actelion's $26 billion-plus deal talks with J&J fall through, now that its PAH drug Opsumit has fallen short in a study designed to grow its…

Sanofi’s Olivier Brandicourt has said acquisitions will help the French drugmaker grow, but the CEO has been unable to pull off a major deal.

M&A